Business Context and Reporting Period
This Form 10-Q is a combined quarterly report for Corteva, Inc. and its subsidiary EIDP, Inc. for the period ended June 30, 2025. Corteva operates as a global leader in agricultural science with two reportable segments: Seed and Crop Protection. EIDP, Inc. is a wholly-owned subsidiary of Corteva that continues to file separate reports due to legacy obligations and preferred stock held by third parties. The filing includes a restatement of EIDP's prior period cash flows due to a material weakness in internal controls regarding intercompany transaction classification, which has since been remediated.
Key Financial Metrics (Six Months Ended June 30, 2025)
| Metric | 2025 (YTD) | 2024 (YTD) | Change |
|---|---|---|---|
| Net Sales | $10,873 million | $10,604 million | +3% |
| Net Income (Corteva) | $1,966 million | $1,472 million | +34% |
| Diluted EPS (Corteva) | $2.87 | $2.10 | +37% |
| Operating EBITDA (Non-GAAP) | $3,353 million | $2,951 million | +14% |
| Cash from Operations (Continuing) | $(1,139) million | $(1,999) million | Improvement |
| Total Debt | $3,629 million | $4,724 million (Jun 2024) | -23% |
| Cash & Equivalents | $2,065 million | $1,839 million (Jun 2024) | +12% |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 3% year-over-year, driven by a 4% volume increase and 1% price increase, partially offset by a 2% unfavorable currency impact. The Seed segment saw volume growth from increased corn acreage in North America, while Crop Protection volume grew due to demand for new products and biologicals in Latin America.
- Profitability Expansion: Net income attributable to Corteva rose 34% to $1.966 billion. This was driven by higher operating EBITDA, lower restructuring charges ($101 million vs. $167 million in 2024), and favorable tax adjustments.
- Cost Management: Cost of Goods Sold (COGS) decreased to 49% of net sales (from 52% in 2024) due to raw material deflation, lower commodity prices, and reduced royalty expenses.
- Discontinued Operations: The company recorded a loss of $77 million from discontinued operations, primarily due to charges related to the MOU with Chemours and DuPont regarding PFAS environmental remediation and the NJ Statewide Settlement.
Guidance, Outlook, and Risks
- Restructuring Program: The "Crop Protection Operations Strategy Restructuring Program" is expected to incur total pre-tax charges of $650–$700 million. As of Q2 2025, $566 million has been recorded. The program aims to deliver $180 million in run-rate savings by 2027.
- Capital Allocation: The company returned approximately $750 million to shareholders in the first half of 2025 via dividends and share repurchases. A $3 billion share buyback program was authorized in November 2024, with approximately $2.98 billion remaining available as of June 30, 2025.
- Legal and Environmental Risks: Significant exposure remains regarding legacy PFAS litigation. A proposed Judicial Consent Order with the State of New Jersey (NJ Statewide Settlement) involves aggregate cash payments of $875 million over 25 years. The company is also subject to ongoing FTC investigations regarding antitrust matters and various product liability lawsuits (e.g., Lorsban).
- Regulatory Risks: Recent funding and staff reductions at U.S. government agencies (EPA, USDA, FDA) may delay regulatory approvals for genetically modified seed products and crop protection chemicals.
Investor Verification Checklist
- PFAS Liability Exposure: Verify the final court approval status of the NJ Statewide Settlement and the potential for additional state-level natural resource damage claims.
- Restructuring Execution: Monitor the timeline for the completion of the Crop Protection restructuring and the realization of the projected $180 million in annual savings.
- Antitrust Litigation: Track the progress of the FTC lawsuit and related private class actions, with trials expected to begin in 2026.
- Currency Hedging: Assess the impact of foreign currency fluctuations (specifically Brazilian Real and Canadian Dollar) on future earnings, given the company's significant international exposure.
- Regulatory Timelines: Evaluate the potential impact of reduced staffing at the EPA and USDA on the commercialization timeline for new product pipelines.